We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. Gordon Foulkes has 25+ years in biopharmaceutical Executive Management R&D and Venture Capital. Most recently he served as founding CEO of Thesan Pharma, raising $45M. Key members of the Thesan team joined FBMT along with acquiring the FBM lead asset. Previously Dr. Foulkes served as the founding CEO of Excaliard Pharmaceuticals from 2007-2009, and resumed that role in 2010, to lead the acquisition of Excaliard by Pfizer in 2011. From 2012 he also served as Exec. Chairman of Redwood BioSciences, where he facilitated its acquisition by Catalent in 2014. From 2005 to 2010, Gordon served as Managing Director at RiverVest Ventures. Previously, Gordon headed R&D, and served on the Boards of multiple biotechnology companies, including OSI (acquired by Astellas for $4 billion in 2010) and Aurora Bio (acquired by Vertex for $590M). He has been involved in more than 15 corporate partnerships and over $215 million in private and public financing.
This speaker's sessions: